Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OC Oral Solution for Sialorrhoea in Parkinson's Disease
NCT01370811Phase 2Completed
- Sponsor
- Orient Pharma Co., Ltd.
- Start
- Aug 2011
- Primary completion
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oxybutynin + clonidine in sialorrhea (4 arms), sponsored by Orient Pharma Co., Ltd. Primary endpoint: Saliva Secreted Rate. Started Aug 2011; status: completed.
02
Drugs
oxybutynin + clonidine
03
Conditions
sialorrhea
Beyond the preview
Go deeper on NCT01370811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01370811.